Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy’s Potential as the First Disease-Modifying Treatment ...

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need ...
Le Lézard

Long-Term Data Presented at the 22nd Annual WORLDSymposiumtm Highlights Tralesinidase Alfa Enzyme Replacement Therapy's Potential as the First Disease-Modifying Treatment ...

Spruce Biosciences, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, announced ...

ICE and CBP’s Face-Recognition App Can’t Actually Verify Who People Are

ICE has used Mobile Fortify to identify immigrants and citizens alike over 100,000 times, by one estimate. It wasn't built to ...

Ultragenyx Pharmaceutical Inc.: Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in ...

Data represents up to 8.5 years of follow-up and are consistent across age, dose, and genotype BLA resubmitted to U.S. FDA in January 2026; Company expects up to six-month review period per FDA guidel ...

Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful ...

Data represents up to 8.5 years of follow-up and are consistent across age, dose, and genotypeBLA resubmitted to U.S. FDA in January 2026; ...
BMJ Open Sport & Exercise Medicine

‘WeekendGo!’ A digital health intervention for promoting children’s physical activity in the family environment: a cluster randomised controlled trial protocol

Insufficient physical activity (PA) among children has become a major global public health concern. The family environment ...